MAIA Biotechnology Inc. (MAIA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MAIA Biotechnology Inc. (MAIA) has a cash flow conversion efficiency ratio of -0.191x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.31 Million) by net assets ($27.76 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see MAIA Biotechnology Inc. stock valuation for the company's overall valuation and market capitalisation.
MAIA Biotechnology Inc. - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how MAIA Biotechnology Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
MAIA Biotechnology Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MAIA Biotechnology Inc. ranked by their cash flow conversion efficiency. See MAIA operating cash to total liabilities to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Asetek A/S
F:A31
|
0.018x |
|
Aerovate Therapeutics Inc
NASDAQ:AVTE
|
-0.032x |
|
Xchanging Solutions Limited
NSE:XCHANGING
|
0.045x |
|
Ahn-Gook Pharmaceutical Co. Ltd
KQ:001540
|
0.086x |
|
JITF Infralogistics Limited
NSE:JITFINFRA
|
0.323x |
|
Novonix Ltd
AU:NVX
|
-0.124x |
|
Redtone International Bhd
KLSE:0032
|
-0.013x |
|
Railcare Group AB (publ)
ST:RAIL
|
0.232x |
Annual Cash Flow Conversion Efficiency for MAIA Biotechnology Inc. (2019–2025)
The table below shows the annual cash flow conversion efficiency of MAIA Biotechnology Inc. from 2019 to 2025. View MAIA stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.38 Million | $-18.84 Million | -7.932x | -83.57% |
| 2024-12-31 | $3.63 Million | $-15.70 Million | -4.321x | +84.22% |
| 2023-12-31 | $477.51K | $-13.07 Million | -27.373x | -1825.30% |
| 2022-12-31 | $8.51 Million | $-12.10 Million | -1.422x | -216.61% |
| 2021-12-31 | $9.18 Million | $-4.12 Million | -0.449x | -139.36% |
| 2020-12-31 | $-1.62 Million | $-1.84 Million | 1.141x | +196.58% |
| 2019-12-31 | $1.32 Million | $-1.57 Million | -1.181x | -- |
About MAIA Biotechnology Inc.
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illin… Read more